Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group aims to explore the tokenization of innovative drug pipeline assets valued at over $1.5 billion, focusing on six major oncology drug pipelines [1][2]. Group 1: Strategic Cooperation Details - Huajian Medical and Chuangsheng Group signed a strategic cooperation agreement to jointly explore the tokenization of innovative drug pipeline assets [1]. - The collaboration involves six innovative oncology drug pipelines, including TST003, TST005, TST786, and three preclinical antibody-drug conjugates TST105, TST106, and TST013 [1]. - These pipelines utilize advanced technologies such as bispecific antibodies, trispecific antibodies, ADCs, and fusion proteins, showcasing global innovation or best-in-class potential [1]. Group 2: Technological and Financial Aspects - Huajian Medical will provide a comprehensive technological solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity integration for the pipeline assets [1]. - The cooperation is expected to lock in the R&D value of high-value pipelines, provide new channels for global capital allocation, and accelerate therapy accessibility [2].

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential RWA tokenization of six core innovative drug pipeline assets valued at over $1.5 billion, representing cutting-edge research in the global oncology treatment field [1][2] - This collaboration marks a significant milestone in the integration of technology and finance, as it represents the first issuance of high-value innovative drug intellectual property assets in RWA form in the capital market [1][2] Summary by Sections Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to explore RWA tokenization of innovative drug pipeline assets [1] - The six core assets involved are TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. in the U.S. [1] RWA Tokenization Benefits - The RWA tokenization aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent, compliant, and efficient opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential tokenization of six innovative drug pipeline assets valued at over $1.5 billion, marking a significant milestone in the integration of technology and finance in the pharmaceutical sector [1][2] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to collaborate on the potential RWA tokenization of innovative drug pipeline assets [1] - The six core innovative drug pipeline assets include TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. (US) [1] Group 2: RWA Tokenization Benefits - The tokenization process aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent and compliant opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Group 3: Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group-B marks a significant milestone in the integration of technology and finance, focusing on the tokenization of innovative drug pipeline assets valued at over $1.5 billion [1] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Chuangsheng Group-B and its subsidiary Transcenta Oncology Inc. [1] - The agreement involves the integration of six core innovative drug pipeline assets into Transcenta Oncology Inc. [1] Group 2: Asset Valuation and Technology Solutions - The total valuation of the integrated assets exceeds $1.5 billion, representing cutting-edge research directions and high technical barriers in the global oncology treatment field [1] - The group will provide a comprehensive technical solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connection for these pipeline assets [1] Group 3: Market Impact - This cooperation signifies the official launch of high-value innovative drug intellectual property assets in the capital market in the form of RWA, highlighting a milestone event in the deep integration of technology and finance [1]

Transcenta Holding Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 有關與華檢醫療控股有限公司及其兩間子公司的戰略合作協議 探索首創真實世界資產代幣化潛在融資用於 創新腫瘤療法研發的業務進展 本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 本公司董事會（「董事會」）欣然公佈，於2025年9月21日，本公司及本公司全資子 公司Transcenta Oncology Inc.（「Transcenta Oncology」）已與華檢醫療控股有限 公司（香港聯合交易所有限公司主板上市公司，股份代號：1931）及其兩間子公司 ETHK Inc.及ETHK HOLDINGS L ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 自願性公告 與 創 勝 集 團 醫 藥 有 限 公 司（06628.HK）簽 署 涉15億美元 創新藥管線資產RWA代幣化之戰略合作協議 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、合作概況與六大創新藥管線亮點 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 及 本 公 司 附 屬 公 司ETHK Inc及 ETHK HOLDINGS LIMITED與創勝集團醫藥有限公司Transcenta ...

Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant increase in stock price following the announcement of a share placement and positive clinical developments in its pipeline assets [1] Group 1: Share Placement and Financials - Chuangsheng Group plans to place 14.4 million shares at a price of HKD 4.33 per share, aiming to raise approximately HKD 59.34 million [1] - The proceeds will be allocated as follows: 40% for clinical development of pipeline assets TST001 and TST002, 30% for advancing promising preclinical pipeline assets including TST801, TST013, and TST786, and 30% for working capital and general purposes [1] Group 2: Clinical Developments - Recent breakthroughs in research and clinical trials have been reported, with TST001 showing a median overall survival (mOS) of 20.4 months in a study involving 82 patients with gastric cancer when used in combination with PD1/CAPOX [1] - Following regulatory approval, Chuangsheng Group is set to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers [1] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, yielding positive early results [1]

Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant stock price increase following the announcement of a share placement to fund clinical development and operational expenses [1] Group 1: Financial Actions - Chuangsheng Group plans to place 14.4 million shares at a price of HKD 4.33 per share, raising approximately HKD 59.34 million [1] - The allocation of the net proceeds includes 40% for clinical development of pipeline assets TST001 and TST002, 30% for advancing promising preclinical pipeline assets such as TST801, TST013, and TST786, and 30% for working capital and general purposes [1] Group 2: Clinical Developments - Recent breakthroughs in research and clinical trials have been reported, particularly for TST001, which has shown a median overall survival (mOS) of 20.4 months in a study involving 82 patients with gastric cancer [1] - TST001 is set to initiate a global Phase III clinical trial for gastric and gastroesophageal cancer upon receiving regulatory approval [1] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China with positive early results [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 6 頁 v 1.3.0 FF305 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 ...